USE OF IVERMECTIN IN PROPHYLAXIS OF COVID 19
DOI:
https://doi.org/10.61164/rmnm.v14i1.1984Keywords:
Ivermectina, Covid 19Abstract
There are more than 2,000 clinical trial registrations worldwide to investigate approved medicines and other candidates for Covid-19, including small molecules and biological medicines, excluding vaccines. Drug repositioning, the most explored strategy to date, has not led to any new antiviral treatment against Covid-19. Remdesivir, despite its emergency approval by the North American regulatory agency, has shown only modest results in clinical studies. Dexamethasone, which contributed to reducing mortality in critically ill patients receiving invasive mechanical ventilation or oxygen, is a corticosteroid that has anti-inflammatory and immunosuppressive properties. Biological medicines, in turn, such as monoclonal antibodies, interferons, specific proteins and anticoagulants are being evaluated in various clinical trials to define their role in disease therapy. The World Health Organization (WHO) warned that the coronavirus may never disappear, even with a possible vaccine, highlighting the urgency of research into new innovative drugs. The most realistic current scenario involves the development of specific antivirals against Sars-CoV-2 for the safe and effective treatment of the disease.
References
Alhazzani W, Evans L, Alshamsi F, Møller MH, Ostermann M, Prescott HC, Arabi YM, Loeb M, Ng Gong M, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A, Du B, Machado F, Wunsch H, Crowther M, Cecconi M, Koh Y, Burry L, Chertow DS, Szczeklik W, Belley-Cote E, Greco M, Bala M, Zarychanski R, Kesecioglu J, McGeer A, Mermel L, Mammen MJ, Nainan Myatra S, Arrington A, Kleinpell R, Citerio G, Lewis K, Bridges E, Memish ZA, Hammond N, Hayden FG, Alshahrani M, Al Duhailib Z, Martin GS, Kaplan LJ, Coopersmith CM, Antonelli M, Rhodes A. Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. Crit Care Med. 2021 Mar 1;49(3):e219-e234. DOI: https://doi.org/10.1097/CCM.0000000000004899
Alunno A, Najm A, Machado PM, Bertheussen H, Burmester GR, Carubbi F, De Marco G, Giacomelli R, Hermine O, Isaacs JD, Koné-Paut I, Magro-Checa C, McInnes I, Meroni PL, Quartuccio L, Ramanan AV, Ramos-Casals M, Rodríguez Carrio J, Schulze-Koops H, Stamm TA, Tas SW, Terrier B, McGonagle DG, Mariette X. EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. Ann Rheum Dis. 2021 Feb 5:annrheumdis-2020-219724. DOI: https://doi.org/10.1136/annrheumdis-2020-219724
Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, De Bon E, Tormene D, Pagnan A, Prandoni P. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010 Nov;8(11):2450-7. DOI: https://doi.org/10.1111/j.1538-7836.2010.04044.x
Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, Edwards KM, Gandhi R, Gallagher J, Muller WJ, O’Horo JC, Shoham S, Murad MH, Mustafa RA, Sultan S, Falck-Ytter Y. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Infectious Diseases Society of America, 11 de abril de 2021. Disponível em: . Acesso em: 12 de abril de 2021. DOI: https://doi.org/10.1093/cid/ciaa478
Caring for people with COVID-19 - Supporting Australia’s healthcare professionals with continually updated, evidence-based clinical guidelines. National COVID-19 Clinical Evidence Taskforce, 2021.
CIHR. RECMAP: COVID-19 Recommendations and Gateway to Contextualization. 2021. Avaliable from: https://covid19.recmap.org/) 7. Chalmers JD, Crichton ML, Goeminne PC, Cao B, Humbert M, Shteinberg M, Antoniou KM, Ulrik CS, Parks H, Wang C, Vandendriessche T, Qu J, Stolz D, Brightling C, Welte T, Aliberti S, Simonds AK, Tonia T, Roche N. Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. Eur Respir J. 2021 Apr 15;57(4):2100048. DOI: https://doi.org/10.1183/13993003.00048-2021
COVID-19 Treatment Guidelines. National Institutes of Health, 2021. Disponível em . Acesso em: 12 de abril de 2021. 9. COVID-19 rapid guideline: managing COVID-19. National Institute for Health and Care Excellence, 23 de março de 2021.
TEERANACHAIDEEKUL, Veerawat et al. Pumpkin seed oil-loaded niosomes for topical application: 5α-reductase inhibitory, anti-inflammatory, and in vivo anti-hair loss effects. Pharmaceuticals, v. 15, n. 8, p. 930, 2022. DOI: https://doi.org/10.3390/ph15080930
VELASCO, Maria Valéria Robles et al. Influência de óleos vegetais brasileiros na resistência mecânica da fibra capilar. Ciências Biofarmacêuticas, v. 12, n. 1, p. 99-106, 2015. DOI: https://doi.org/10.19277/BBR.12.1.108
ZHOU, You et al. Study on the chemical constituents of nut oil from Prunus mira Koehne and the mechanism of promoting hair growth. Journal of ethnopharmacology, v. 258, p. 112831, 2020. DOI: https://doi.org/10.1016/j.jep.2020.112831
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Revista Multidisciplinar do Nordeste Mineiro
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
